Serum macrophage inhibitory cytokine‐1 as a clinical marker for non–small cell lung cancer

The aim of this study was to investigate the value of serum macrophage inhibitory factor‐1 (MIC‐1) level in patients with non–small cell lung cancer (NSCLC). Serum samples from 296 patients with NSCLC and 240 healthy controls were collected. The levels of serum MIC‐1 were determined by ELISA. The se...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chunhua, Li, Li, Wang, Wei, Zhang, Qian, Zhang, Xiuwei, Yang, Rusong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957168/
https://www.ncbi.nlm.nih.gov/pubmed/33605059
http://dx.doi.org/10.1111/jcmm.16360
Descripción
Sumario:The aim of this study was to investigate the value of serum macrophage inhibitory factor‐1 (MIC‐1) level in patients with non–small cell lung cancer (NSCLC). Serum samples from 296 patients with NSCLC and 240 healthy controls were collected. The levels of serum MIC‐1 were determined by ELISA. The serum MIC‐1 levels in NSCLC patients were higher than that of the controls (P <.001). Univariate and multivariate Cox regression analysis showed that serum MIC‐1 was an independent prognostic indicator of OS and PFS. Serum MIC‐1 is a valuable biomarker for the diagnosis and prognosis of NSCLC.

Ejemplares similares